Theravance Biopharma Reports Impressive Financial Results for Q3
Theravance Biopharma, Inc. (NASDAQ: TBPH) has reported its financial and operational achievements for the third quarter of 2025, showcasing remarkable performance metrics. YUPELRI net sales achieved an all-time high of $71.4 million, marking a 15% increase compared to the previous year. This growth reflects sustained customer demand and favorable pricing strategies.
Striking Financial Highlights
In addition to its record sales, the company revealed that it has reached non-GAAP breakeven, reinforcing its commitment to financial discipline. "Theravance delivered strong results in the third quarter, highlighted by record YUPELRI net sales and the achievement of non-GAAP breakeven," stated Rick E Winningham, Chief Executive Officer of Theravance Biopharma.
Operational Milestones and Innovations
The recent completion of the pivotal Phase 3 CYPRESS study open-label portion is a significant action toward advancing ampreloxetine, a medication in development aimed at addressing neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Topline results are anticipated in the first quarter of 2026.
Upcoming KOL Event and Engagement
On December 8, Theravance Biopharma plans to host a key opinion leader (KOL) event, focusing on ampreloxetine's potential in treating nOH. This event will feature expert Dr. Horacio Kaufmann M.D., who will delve into the unmet needs of patients with MSA and provide insights on the promising potential of this investigational drug.
Strong Financial Position
As of the end of the third quarter, Theravance Biopharma maintained a robust cash position totaling approximately $333 million, without any debt. The strategic allocation of resources reinforces its ability to pursue critical clinical programs and deliver shareholder value.
Insights into R&D and Revenue Growth
The total revenue for Q3 2025 was recorded at $20 million, fully derived from the collaboration with Viatris, with a 19% increase from the previous year’s same quarter. This revenue included a substantial increase in revenues related to YUPELRI, aligning with the company's growth strategy.
Guidance for 2025
Theravance Biopharma provided updated guidance for its operational expenditures in R&D and SG&A, maintaining expectations for the year within the realms of strong fiscal management. The anticipated R&D costs for 2025 are set between $32 million and $38 million, with SG&A expected to fall between $50 million to $60 million, excluding share-based compensation.
Community Awareness Campaigns
In October 2025, the company launched a disease education campaign to enhance awareness of neurogenic orthostatic hypotension linked with MSA. This initiative aims to improve the understanding of this rare disorder among healthcare professionals.
Future Potential and Strategic Initiatives
The formation of a Strategic Review Committee reflects Theravance's commitment to continually explore various avenues for enhancing shareholder value. They are evaluating numerous alternatives to fortify their strategic positioning and capitalize on future opportunities.
About Theravance Biopharma
Theravance Biopharma, Inc. is dedicated to delivering innovative therapies that have a measurable impact on improving patients' lives. Their portfolio includes FDA-approved YUPELRI, a once-daily inhalation solution for chronic obstructive pulmonary disease (COPD) alongside ampreloxetine, which holds potential for treating symptomatic nOH in patients with MSA. The company remains focused on driving shareholder value while maintaining its commitment to rigorous clinical research.
Frequently Asked Questions
1. What were the key highlights of Theravance's Q3 2025 report?
Theravance reported record YUPELRI net sales, achieving $71.4 million which is a 15% year-over-year increase, and reached non-GAAP breakeven.
2. What is the significance of ampreloxetine?
Ampreloxetine is an investigational drug targeted at treating neurogenic orthostatic hypotension in patients with multiple system atrophy, with pivotal study results expected in early 2026.
3. How is Theravance managing its finances?
Theravance maintains a strong cash position of about $333 million and has no debt, which indicates sustainable financial health.
4. What events is Theravance hosting?
The company is set to host a KOL event on December 8 to discuss ampreloxetine and its implications for treating nOH in MSA patients.
5. How does Theravance plan to support its clinical trials?
Theravance continues to focus on disciplined capital allocation, investing strategically in R&D while maintaining strong operational management to support its clinical trials and growth initiatives.
